HRA Pharma is an emerging European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide.
A pioneer in emergency contraception since the launch of its first product in 1999, NorLevo?, HRA Pharma has engineered a robust portfolio and pipeline in the fields of reproductive health and endocrinology which it maximizes through in-licensing and out-licensing agreements.
The company targets and tackles therapeutic gaps and uses innovative marketing solutions and socially-conscious programs to promote healthy management of drug and diseases worldwide.
Headquartered in Paris, France with local teams based at subsidiaries in Germany (Bochum), the United Kingdom (London), Italy (Roma), Spain (Madrid) and the United States (New York City), HRA Pharma is privately-owned with sales over ?33 million in 2008. The company has forged a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 60 countries across the globe.
Visit the company web site at: http://www.hra-pharma.com.